Publication | Closed Access
Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial
298
Citations
13
References
2009
Year
After a 47-month median follow-up, 1 year of trastuzumab given sequentially after adjuvant chemotherapy was not associated with a statistically significant decrease in the risk of relapse.
| Year | Citations | |
|---|---|---|
Page 1
Page 1